Biologics

India’s pharmaceutical regulatory system faces an uncomfortable truth—the framework that served generic drugs brilliantly for decades is increasingly obsolete. The present structure, developed primarily for chemical generics, struggles mightily to regulate biologics, cell therapy, and cutting-edge advanced medicines requiring specialised standards. Industry experts warn that generics are becoming yesterday’s business as the global pharmaceutical market […]

India’s pharmaceutical industry is simultaneously pursuing two revolutionary paths that seem unrelated but share a common thread—saving lives more ethically and effectively. The country recently eliminated mandatory animal testing for drug development whilst simultaneously ramping up efforts against antimicrobial resistance that threatens to kill 10 million people annually by 2050. These aren’t minor policy adjustments

India’s biotechnology sector buzzes with potential, yet a frustrating disconnect persists between government promises and ground realities. Whilst the Department of Biotechnology launches ambitious schemes worth thousands of crores, startup founders in Bengaluru and Hyderabad tell different stories. They speak of delayed funding, bureaucratic labyrinths, and support that sounds impressive on paper but rarely materialises

There’s a particular irony in modern medicine: the most sophisticated treatments often look deceptively simple. A clear vial containing colourless liquid might cost thousands of pounds per dose, yet inside swim precisely engineered proteins capable of seeking out and destroying cancer cells whilst leaving healthy tissue untouched. These are monoclonal antibodies—amongst the most revolutionary therapeutics

India’s pharmaceutical sector stands at a paradoxical crossroads where technological capability dramatically outpaces clinical execution, creating both extraordinary opportunity and persistent frustration. The nation is rapidly emerging as a significant global player in drug discovery, driven by its highly skilled scientific workforce, substantial cost advantages, and growing investments from domestic and international sources seeking alternatives

India’s biologics market is experiencing a transformation that’s catching global pharmaceutical giants off guard and reshaping competitive dynamics in biotechnology. Led by the explosive rise of bioconjugates and biosimilars as major growth drivers, India is rapidly evolving from a generic drugs manufacturer into a sophisticated biotech innovator capable of producing some of the world’s most